United Therapeutics Corp
(BSP:U2TH34)
R$
127
(0%)
Market Cap: 108.94 Bil
Enterprise Value: 95.29 Bil
PE Ratio: 17.45
PB Ratio: 3.25
GF Score: 26/100 United Therapeutics Corporation at Wells Fargo Healthcare Conference Transcript
Sep 08, 2026 / 03:00PM GMT
Benjamin Burnett
Wells Fargo Securities LLC - Analyst
I think we're ready to go ahead and get started. My name is Ben Burnett, biotech analyst at Wells Fargo, and I'm pleased to be here with United Therapeutics management team. We have Martine Rothblatt, CEO; and James Edgemond, CFO. So thank you for being here.
Martine Rothblatt
United Therapeutics Corporation - Chairman of the Board, Chief Executive Officer
Thanks, Ben.
Benjamin Burnett
Wells Fargo Securities LLC - Analyst
I think maybe just to kind of, kick us off, just kind of start by giving us a quick overview of sort of the business and some of the near-term events that we should be focused on.
Martine Rothblatt
United Therapeutics Corporation - Chairman of the Board, Chief Executive Officer
Sure, Ben. Glad to do so. United Therapeutics is right now at a major inflection point where we are rolling out 14 new products over the next few years that cumulatively will provide us, we believe, somewhere between $50
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot